Summary & Overview
HCPCS J0693: Injection, Cefiderocol, 5 mg
HCPCS Level II code J0693 denotes the injection of cefiderocol in 5 mg units, representing administration of a parenteral novel siderophore cephalosporin for serious Gram-negative infections. This code matters nationally because cefiderocol is often reserved for multidrug-resistant infections and its use can carry substantial drug and administration costs, affecting payer coverage decisions and hospital pharmacy budgets.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for J0693, typical sites of service, and the relevance of precise coding for billing and utilization tracking. The publication outlines expected benchmarks and policy considerations such as coverage criteria, prior authorization trends, and billing practices tied to inpatient and outpatient infusion services. It also summarizes common modifiers associated with HCPCS billing generally and notes where data was not supplied in the input.
This summary is intended for a national audience of billing professionals, pharmacists, hospital administrators, and policy analysts who need a clear reference for use, billing context, and payer relevance of HCPCS Level II code J0693.
Billing Code Overview
HCPCS Level II code J0693 represents injection, cefiderocol, 5 mg. This code describes the administration of the intravenous antibiotic cefiderocol, typically used for treatment of serious Gram-negative bacterial infections. The service type is an intravenous antimicrobial injection. The typical site of service is an outpatient infusion center, hospital inpatient setting, or other clinical infusion facility depending on clinical need and administration requirements.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A hospitalized adult patient with a confirmed or suspected multidrug-resistant Gram-negative infection (for example, complicated urinary tract infection, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or bloodstream infection) receives intravenous cefiderocol for targeted therapy. The antimicrobial stewardship team or infectious disease consultant documents indication, culture and susceptibility results, dose, frequency, and duration. Pharmacy prepares J0693 as a per-5 mg unit for infusion; billing reports the total units administered per dose and per day. Typical workflow: physician orders cefiderocol in the electronic medical record with indication and dosing; nursing verifies order and obtains intravenous access; pharmacy compounds and labels the dose; nurse administers infusion and documents administration time, lot number, and patient tolerance; billing uses J0693 with relevant modifiers to report unusual circumstances (for example, increased procedural services, discontinued service, or anesthesia-related modifiers) and links to the primary ICD-10 diagnosis for medical necessity.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased Procedural Services | Use when documentation supports substantially greater services than typical for administering therapy (rare for standard IV infusion; may apply with complex infusion management). |